Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

  • Bachiller, Mireia
  • Ferruz Capapey, Noelia, 1988-
  • Guedan, Sonia
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the co-expression of CD19 and BCMA in NHL, we hypothesized that dual targeting could enhance long-term efficacy. We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, and loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. Comparison with anti-CD19/CD20 or anti-CD19/CD22 dual targeting was also performed. We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors after optimization to minimize competition for cellular resources. Co-transduced T cells, called ARI0003, effectively targeted NHL tumor cells with high avidity, outperforming anti-CD19 CAR-T cells and other dual-targeting approaches both in vitro and in vivo, particularly in low CD19 antigen density models. ARI0003 maintained effectiveness post-CD19 CAR-T treatment in xenograft models and in spheroids from relapsed CART-treated patients. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with a reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase 1 clinical trial (CARTD-BG-01; this study was registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL., This study was supported by research funding from “'la Caixa” Foundation to M.J. (LCF/PR/SP23/52950004); the Spanish Ministry of Science and Innovation under a Ramon y Cajal grant RYC2018-024442-I to S.G. and PID2020-119692RB-C22 to C.F.; the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116026 to S.G. (this joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations), the Spanish Association Against Cancer (INVES222988RODR to A.R.-G.), and the AGAUR_INVESTIGO22 100028TC1 grant, within the framework of the Recovery, Transformation, and Resilience Plan, funded by the European Union’s NextGenerationEU Recovery Mechanism. C.D.-L. was supported by a personal "Formación de personal investigador" fellowship from the Ministry of Economy and competitiveness (PRE2018-083797) associated with the project SAF2017-88275-R to P.P.-G. We also thank the Generalitat de Catalunya for support (AGAUR 2021-SGR-01294) to P.P.-G. M.O.-M. was granted a "Formacion para investigadores en el ámbito de la Investigacin sanitaria" predoctoral training grant (IFI18/00035). B.M.-A. was supported by the Miguel Servet program (grant no. CP21/00111) of the Institute of Health Carlos III. We also acknowledge the support of the CERCA Programme/Generalitat de Catalunya. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. We thank the Flow Cytometry and Cell Sorting core facility of Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS) for their technical help. We also thank the animal facility of the University of Barcelona.
Repisalud
Publicación Artículo científico (JournalArticle)

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.

  • Bachiller, Mireia
  • Barceló-Genestar, Nina
  • Rodriguez-Garcia, Alba
  • Alserawan, Leticia
  • Dobaño-López, Cèlia
  • Giménez-Alejandre, Marta
  • Castellsagué, Joan
  • Colell, Salut
  • Otero-Mateo, Marc
  • Antoñana-Vildosola, Asier
  • Español-Rego, Marta
  • Ferruz, Noelia
  • Pascal, Mariona
  • Martín-Antonio, Beatriz
  • Anguela, Xavier M
  • Fillat, Cristina
  • Olesti, Eulàlia
  • Calvo, Gonzalo
  • Juan, Manel
  • Delgado, Julio
  • Pérez-Galán, Patricia
  • Urbano-Ispizua, Álvaro
  • Guedan, Sonia
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the co-expression of CD19 and BCMA in NHL, we hypothesized that dual targeting could enhance long-term efficacy. We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, and loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. Comparison with anti-CD19/CD20 or anti-CD19/CD22 dual targeting was also performed. We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors after optimization to minimize competition for cellular resources. Co-transduced T cells, called ARI0003, effectively targeted NHL tumor cells with high avidity, outperforming anti-CD19 CAR-T cells and other dual-targeting approaches both in vitro and in vivo, particularly in low CD19 antigen density models. ARI0003 maintained effectiveness post-CD19 CAR-T treatment in xenograft models and in spheroids from relapsed CART-treated patients. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with a reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase 1 clinical trial (CARTD-BG-01; this study was registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment

  • Parés, Marta
  • Pallaruelo-Santamaría, Víctor
  • Fillat, Cristina
  • Martínez-Latorre, Javier|||0000-0001-5421-5371
  • Candela-Noguera, Vicente
  • Soriano-Teruel, Paula
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant malignancies, with limited efficacy to conventional treatments such as surgical resection or chemotherapy. This clinical scenario underscores the need for novel therapeutic strategies. The development of multifunctional platforms capable of targeting tumors through multiple mechanisms offers an innovative strategy to overcome this challenge. Lipid nanoparticles (LNPs) offer a versatile platform capable of efficiently delivering genetic material. Moreover, through surface functionalization it is feasible to improve LNP performance optimizing therapeutic outcomes in a single formulation. Here, we explored a dual functionalization strategy of the LNP for tumor targeting and tumor remodeling to improve treatment efficacy. LNPs were designed for delivering reporter DNA plasmid or mRNA into the PDAC cellular models Capan-2 and PANC-1. The DNA plasmid contains a pancreatic cancer-specific chimeric promoter for transcriptional specificity to PDAC cells. Besides, LNPs were functionalized with folate and an anti-CD47 antibody to both target the folate receptor in PDAC cells and block CD47-mediated immune evasion. Both pDNA and mRNA LNPs targeted PDAC cells in a dose-dependent manner, with mRNA-LNPs demonstrating more efficient transfection. Notably, LNPs functionalized with the anti-CD47 antibody increased phagocytosis in vitro, and promoted an inflammatory phenotype of M1-like macrophages in mouse Capan-2 xenografts. This combinatorial design of the formulated LNP represents an innovative therapeutic strategy and opens future perspectives in the search for effective treatments for PDAC. Keywords: Lipid nanoparticles; Immunotherapy; ACD47; Folate; Macrophages; Pancreatic cancer, This research was supported by European Union s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020- 119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovacion ¿ and by the European Regional Development Fund A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from la Caixa Foundation under agreement LCF/PR/ SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models

  • Otero, Marc
  • Estrany Castillo, Francesc
  • Pembaur, Daniel
  • Gracia Batllori, Albert
  • Parés, Marta
  • Díaz Permanyer, Adrià
  • Brugada-Vilà, Pau
  • Fornaguera, Cristina
  • Cascante, Anna
  • Borrós, Salvador
  • Kreppel, Florian
  • Fillat, Cristina
Enhancing the safety and efficacy of systemically administered oncolytic adenoviruses remains a significant challenge to achieve effective targeting of primary tumors and disseminated disease. Intravenous administration exposes viral particles to various blood components interfering with their therapeutic activity. To protect adenoviruses from the inactivating factors we developed a shielding strategy based on a nanoparticle formulation reactive to a specific-site in the hexon hypervariable region 1. We propose a novel coating approach based on the combination of a bioresponsive oligopeptide-modified poly(β-aminoester)s (OM-PBAE-CRRR) and an irreversible linear PEG polymer with protruding ends to shield the oncolytic adenovirus AdNuPARc-E (PEPB). The formulated virus displays a slight delay in the transduction and replicative capacity at early time points that normalizes in a few days. Interestingly, similar oncolytic efficacy to the naked virus was observed in vitro, with enhanced antitumor effect in vivo in a pancreatic cancer model. In accordance, PEPB showed significantly enhanced pharmacokinetics and increased liver and tumor transduction in the xenograft model. In the presence of neutralizing antibodies (NAbs) coated viral particles maintained the infectivity and the replication capacity. Notably, in pre-immunized immunocompetent mice, protection from NAbs resulted in a higher viral accumulation in tumors than in the liver and was associated with significant antitumor activity. In summary, our findings indicate that the proposed formulation PEPB —the oncolytic adenovirus AdNuPARc-E site-specifically shielded with OM-PBAE-CRRR/PEG — offers a promising approach to improve tumor targeting after systemic administration, even in the presence of pre-existing neutralizing antibodies., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model

  • Mateu-Bosch, Anna
  • Segur-Bailach, Eulàlia
  • Muñoz-Moreno, Emma
  • Barallobre, María-José
  • Arbones, Maria L.
  • Gea-Sorlí, Sabrina
  • Tort, Frederic
  • Ribes, Antonia
  • García-Villoria, Judit
  • Fillat, Cristina
Glutaric aciduria type 1 (GA1) is a rare inherited metabolic disorder caused by a deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), with accumulation of neurotoxic metabolites, resulting in a complex movement disorder, irreversible brain damage, and premature death in untreated individuals. While early diagnosis and a lysine restricted diet can extend survival, they do not prevent neurological damage in approximately one-third of treated patients, and more effective therapies are required. Here we report the efficacy of adeno-associated virus 9 (AAV9)-mediated systemic delivery of human GCDH at preventing a high lysine diet (HLD)-induced phenotype in Gcdh−/− mice. Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum. This treatment protects the mice from HLD-aggressive phenotype with all mice surviving this exposure; in stark contrast, a lack of treatment on an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues, with about 60% death due to brain accumulation of toxic lysine metabolites. AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination. Magnetic resonance imaging findings show protection against striatal injury. Altogether, these results provide preclinical evidence to support AAV-GCDH gene therapy for GA1., This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. A.M.-B. is the recipient of a PIF-Salut predoctoral contract from Generalitat de Catalunya, Spain. This work was supported by grants to CF from the CIVP19A5949-Fundación Ramón Areces, ACCI-CIBERER, and PID2020-119692RB-C22 Spanish Ministerio de Ciencia e Innovación, with partial support from Fundacio La Caixa, the Generalitat de Catalunya SGR21/01169 and from ISCIII RICORS RD21/0017/0012. We also acknowledge all members of the CHARLIE Consortium (www.charlie.science) for their helpful discussions. This project also received support from Instituto de Salud Carlos III (ISCIII) AC20/00088 under the frame of E-Rare-3, the ERA-Net for Research on Rare Diseases, EJPRD (grant nr: 825575). CIBERER is an initiative of the ISCIII. We also acknowledge the support of CERCA Programme/Generalitat de Catalunya. Graphical abstract was created with Biorender.com., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

  • Bachiller, Mireia
  • Ferruz Capapey, Noelia, 1988-
  • Guedan, Sonia
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the co-expression of CD19 and BCMA in NHL, we hypothesized that dual targeting could enhance long-term efficacy. We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, and loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. Comparison with anti-CD19/CD20 or anti-CD19/CD22 dual targeting was also performed. We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors after optimization to minimize competition for cellular resources. Co-transduced T cells, called ARI0003, effectively targeted NHL tumor cells with high avidity, outperforming anti-CD19 CAR-T cells and other dual-targeting approaches both in vitro and in vivo, particularly in low CD19 antigen density models. ARI0003 maintained effectiveness post-CD19 CAR-T treatment in xenograft models and in spheroids from relapsed CART-treated patients. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with a reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase 1 clinical trial (CARTD-BG-01; this study was registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL., This study was supported by research funding from “'la Caixa” Foundation to M.J. (LCF/PR/SP23/52950004); the Spanish Ministry of Science and Innovation under a Ramon y Cajal grant RYC2018-024442-I to S.G. and PID2020-119692RB-C22 to C.F.; the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116026 to S.G. (this joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations), the Spanish Association Against Cancer (INVES222988RODR to A.R.-G.), and the AGAUR_INVESTIGO22 100028TC1 grant, within the framework of the Recovery, Transformation, and Resilience Plan, funded by the European Union’s NextGenerationEU Recovery Mechanism. C.D.-L. was supported by a personal "Formación de personal investigador" fellowship from the Ministry of Economy and competitiveness (PRE2018-083797) associated with the project SAF2017-88275-R to P.P.-G. We also thank the Generalitat de Catalunya for support (AGAUR 2021-SGR-01294) to P.P.-G. M.O.-M. was granted a "Formacion para investigadores en el ámbito de la Investigacin sanitaria" predoctoral training grant (IFI18/00035). B.M.-A. was supported by the Miguel Servet program (grant no. CP21/00111) of the Institute of Health Carlos III. We also acknowledge the support of the CERCA Programme/Generalitat de Catalunya. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. We thank the Flow Cytometry and Cell Sorting core facility of Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS) for their technical help. We also thank the animal facility of the University of Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models

  • Otero, Marc
  • Estrany Castillo, Francesc
  • Pembaur, Daniel
  • Gracia Batllori, Albert
  • Parés, Marta
  • Díaz Permanyer, Adrià
  • Brugada-Vilà, Pau
  • Fornaguera, Cristina
  • Cascante, Anna
  • Borrós, Salvador
  • Kreppel, Florian
  • Fillat, Cristina
Enhancing the safety and efficacy of systemically administered oncolytic adenoviruses remains a significant challenge to achieve effective targeting of primary tumors and disseminated disease. Intravenous administration exposes viral particles to various blood components interfering with their therapeutic activity. To protect adenoviruses from the inactivating factors we developed a shielding strategy based on a nanoparticle formulation reactive to a specific-site in the hexon hypervariable region 1. We propose a novel coating approach based on the combination of a bioresponsive oligopeptide-modified poly(β-aminoester)s (OM-PBAE-CRRR) and an irreversible linear PEG polymer with protruding ends to shield the oncolytic adenovirus AdNuPARc-E (PEPB). The formulated virus displays a slight delay in the transduction and replicative capacity at early time points that normalizes in a few days. Interestingly, similar oncolytic efficacy to the naked virus was observed in vitro, with enhanced antitumor effect in vivo in a pancreatic cancer model. In accordance, PEPB showed significantly enhanced pharmacokinetics and increased liver and tumor transduction in the xenograft model. In the presence of neutralizing antibodies (NAbs) coated viral particles maintained the infectivity and the replication capacity. Notably, in pre-immunized immunocompetent mice, protection from NAbs resulted in a higher viral accumulation in tumors than in the liver and was associated with significant antitumor activity. In summary, our findings indicate that the proposed formulation PEPB —the oncolytic adenovirus AdNuPARc-E site-specifically shielded with OM-PBAE-CRRR/PEG — offers a promising approach to improve tumor targeting after systemic administration, even in the presence of pre-existing neutralizing antibodies., info:eu-repo/semantics/publishedVersion